The Cas9-expression vector, lentiCas9-Blast, was a gift from Dr. Feng Zhang at the Broad Institute of Harvard and MIT (Addgene plasmid # 52962). Cas9 protein was introduced to human AML cell lines by lentiviral transduction and selected with 10 µg/mL
Blasticidin (Thermo, R21001). The sgRNA-expression vectors, LRG (
Lenti_sgRNA_EFS_GFP) (Addgene plasmid # 65656) and
LRCherry2.1 (Addgene plasmid # 108099), were gifts from Christopher Vakoc. Cells were transduced with sgRNA lentivirus and sorted for GFP+ cells 48 hours following transduction (except for negative-selection competition assay). CRISPR sgRNA sequences used were:
sgKAT6A-1: CATACCACTGTTGCCACAGT; sgKAT6A-2: TTCGAGTGAAGGCCTTACGG;
sgKAT6A-3: CTCATCTCCTGTGCCGACTG; sgKAT6A-4: TTAGTGTTGAGCCGATAAAG;
sgKat6a-1: TGCAGCTCCTGTCGTGACCA; sgKat6a-2: GCTATTGCCGCAGTCCGCGC;
sgKat6a-3: CTCGTCTCCTGCGCGGACTG; sgKat6a-4: CGGCGCTATGCTAATCCAAT;
sgKat6a-5: TATGTCAGATATGCCGACCT; sgKat6a-6: CTCAATGCACTGCCACCGTA;
sgRosa26: GAAGATGGGCGGGAGTCTTC; sgNonTarget: ATTGAGAATTCGTTTCAAGG.
Except for the negative selection competition assay which used all the sgRNAs, in other assays: human sgKAT6A-2 and mouse sgKat6a-6 were used, if not indicated otherwise.
Yan F., Li J., Milosevic J., Petroni R., Liu S., Shi Z., Yuan S., Reynaga J.M., Qi Y., Rico J., Yu S., Liu Y., Rokudai S., Palmisiano N., Meyer S.E., Sung P.J., Wan L., Lan F., Garcia B.A., Stanger B.Z., Sykes D.B, & Andrés Blanco M. (2022). KAT6A and ENL form an epigenetic transcriptional control module to drive critical leukemogenic gene expression programs. Cancer discovery, 12(3), 792-811.